Publications by Dr Ally Speight - ePrints

Browsing publications by Dr Ally Speight.

Newcastle Authors	Title	Year
Dr Nicola Wyatt Dr Hannah Watson Jennifer Doyle Dr Ally Speight Professor Christopher Stewart et al.	Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research	2024
Dr David Nylander Professor John Leeds Dr John Perry Dr Manjusha Narayanan Dr Christian Dipper et al.	Bacterial contamination of endoscopist and assistant face visors during gastrointestinal endoscopy: A pilot study	2023
Dr Ally Speight Professor Chris Lamb	Establishing key performance indicators for inflammatory bowel disease in the UK	2023
Professor Chris Lamb Professor Sophie Hambleton Dr Ally Speight	Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition	2023
Dr Kristian Williams Abigail Gault Dr Amy Anderson Professor Christopher Stewart Professor Chris Lamb et al.	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations	2023
Dr Ally Speight	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab	2021
Dr Nicola Wyatt Dr Ally Speight Professor Christopher Stewart Emeritus Professor John Kirby Professor Chris Lamb et al.	Targeting leukocyte trafficking in inflammatory bowel disease	2021
Emily Glover Dr Ally Speight Dr Despina Televantou Dr Stephanie Needham Professor Neil Sheerin et al.	Immunosuppression-induced clonal T-cell lymphoproliferative disease causing severe diarrhoea mimicking coeliac disease following renal transplantation: a case report	2020
Dr Ally Speight Dr Nicholas Thompson	Randomised clinical trial: Combined impact and resistance training in adults with stable Crohn’s disease	2020
Dr Ally Speight Dr John Mansfield	Editorial: how effective is vedolizumab in the 'real world'?	2017